Axon Enterprise enters its May 28 Q1 results with short sellers quietly rebuilding positions through a month of broad price weakness — a pairing that sets up an interesting tension ahead of the print.
The short-side rebuild is the standout data point of the past few weeks. Short interest has climbed 25% over the past month to 4.5% of the free float, with nearly all of that move concentrated in late April. From roughly 2.7 million shares short in mid-April, the estimated position has jumped to 3.6 million — a 30% rise in under three weeks. The ORTEX short score has tracked the move higher, reaching 42.8 this week from 37.8 on April 22. That's a meaningful acceleration, even if the absolute short score remains moderate in the broader universe. The stock itself is down 8% over the past month to $380.60, and off roughly 31% year-to-date — a significant de-rating that has provided cover for shorts to add without chasing.
What the lending market says is more nuanced. Availability remains loose — borrowing costs are running just 0.46%, essentially flat over the past month, and the borrow market shows no sign of stress. That means the short-side growth is deliberate positioning, not the product of a squeeze or a forced unwind. Availability in the lending pool is ample relative to the volume of shares being borrowed. Options positioning is mild by comparison: the put/call ratio is 1.09, modestly above its 20-day average of 1.06, with a z-score of 0.7 — directionally cautious but far from the defensive extremes seen in late March, when the PCR ran above 1.3 for weeks. Overall, positioning looks more cautious than crowded.
The Street has been adjusting targets down while maintaining positive ratings — a "buy, but cheaper" posture that is now almost universal. JP Morgan cut its target from $925 to $750 in mid-April, keeping Overweight. Goldman Sachs trimmed to $625 from $720 in early April, also maintaining Buy. TD Cowen cut to $825. The mean price target sits around $708, implying roughly 86% upside from the current price. At face value that gap is striking, but it reflects how far the stock has sold off — not a sudden burst of analyst optimism. The consensus remains a clean buy, with 10 buy ratings and no sells visible in the dataset. On valuation, the P/E has compressed to 43.8x from nearly 49x a month ago. EV/EBITDA is at 29.8x, down roughly two points over the same period. The stock is cheaper than it has been in months, though not cheap by any traditional measure.
The bull case rests on Axon's dominance in public safety technology, a growing software and AI layer, and a bookings backlog that points to durable revenue growth. Bears focus on rising competition in the law enforcement technology space and the risk that hardware demand from the Connected Devices segment — the revenue workhorse — proves cyclical rather than recurring. Both sides of that debate will get a data point on May 28.
The last earnings reaction in February was dramatic: the stock jumped 24% the following day and held most of that gain through the week. That move came after a period of heavy options defensiveness, which has since faded. How the current short rebuild interacts with any surprise in the Q1 print — in either direction — is the setup worth watching between now and month-end.
See the live data behind this article on ORTEX.
Open AXON on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
